Exondys classification?

See the DrugPatentWatch profile for Exondys

What is Exondys' classification under the FDA approval process?

Exondys (eteplirsen) is a type of antisense oligonucleotide, a class of drugs designed to selectively inhibit the expression of specific genes.

How was Exondys approved by the FDA?

Exondys was approved by the FDA under the accelerated approval pathway in 2016. This pathway enables the FDA to approve a medication based on a surrogate endpoint, which is a marker that is used as a substitute for a clinical endpoint (i.e., a direct measure of the effect of the drug on the outcome).

What does this mean for Exondys' approval status?

Exondys' accelerated approval is conditional on the drug's sponsor, Sarepta Therapeutics, conducting additional clinical trials to confirm the drug's efficacy and safety.

What are the implications of Exondys' accelerated approval?

Exondys' accelerated approval means that it has been made available to patients more quickly than under the traditional FDA approval process. However, it also means that the drug's approval may be withdrawn if the confirmatory trials do not show the expected benefits.

Can anyone try to challenge Exondys' accelerated approval?

Yes, other companies or organizations can attempt to challenge Exondys' accelerated approval by requesting a new review of the drug's efficacy and safety.

Sources:
[1] https://www.drugpatentwatch.com/drug/exondys
[2] https://www.sarepatherapeutics.com/our-science/exondys-eteplirsen/
[3] FDA news release: FDA Approves First Treatment for Duchenne Muscular Dystrophy Caused by Nonsense Mutations in the DMD Gene (2016)

* DrugPatentWatch.com provides more information on Exondys' patent status and potential generic competition.